JP2019502751A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019502751A5 JP2019502751A5 JP2018550317A JP2018550317A JP2019502751A5 JP 2019502751 A5 JP2019502751 A5 JP 2019502751A5 JP 2018550317 A JP2018550317 A JP 2018550317A JP 2018550317 A JP2018550317 A JP 2018550317A JP 2019502751 A5 JP2019502751 A5 JP 2019502751A5
- Authority
- JP
- Japan
- Prior art keywords
- less
- impurities
- active ingredient
- months
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012535 impurity Substances 0.000 claims description 39
- 229960005079 pemetrexed Drugs 0.000 claims description 21
- 239000003963 antioxidant agent Substances 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 19
- 230000003078 antioxidant effect Effects 0.000 claims description 18
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 claims description 17
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 15
- 239000001301 oxygen Substances 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 12
- 239000012669 liquid formulation Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims 9
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 4
- 239000007789 gas Substances 0.000 claims 2
- NYDXNILOWQXUOF-UHFFFAOYSA-L disodium;2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate Chemical group [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)NC(CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-UHFFFAOYSA-L 0.000 claims 1
- 229960003349 pemetrexed disodium Drugs 0.000 claims 1
- 229940033654 pemetrexed disodium heptahydrate Drugs 0.000 claims 1
- 229940035024 thioglycerol Drugs 0.000 claims 1
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-N pemetrexed Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-N 0.000 description 21
- 239000000203 mixture Substances 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- 238000013112 stability test Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 238000002845 discoloration Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000004201 L-cysteine Substances 0.000 description 2
- 235000013878 L-cysteine Nutrition 0.000 description 2
- 229940110282 alimta Drugs 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229910052979 sodium sulfide Inorganic materials 0.000 description 2
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 201000005282 malignant pleural mesothelioma Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150178339A KR101693675B1 (ko) | 2015-12-14 | 2015-12-14 | 페메트렉시드 또는 그의 약제학적으로 허용가능한 염을 함유하는 안정화된 약학조성물 |
| KR10-2015-0178339 | 2015-12-14 | ||
| PCT/KR2016/014594 WO2017105059A1 (ko) | 2015-12-14 | 2016-12-13 | 페메트렉시드 또는 그의 약제학적으로 허용가능한 염을 함유하는 안정화된 약학조성물 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020091920A Division JP2020125359A (ja) | 2015-12-14 | 2020-05-27 | ペメトレキセドまたはその薬剤学的に許容可能な塩を含有する安定化された薬学組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019502751A JP2019502751A (ja) | 2019-01-31 |
| JP2019502751A5 true JP2019502751A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2019-08-29 |
Family
ID=57832487
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018550317A Pending JP2019502751A (ja) | 2015-12-14 | 2016-12-13 | ペメトレキセドまたはその薬剤学的に許容可能な塩を含有する安定化された薬学組成物 |
| JP2020091920A Pending JP2020125359A (ja) | 2015-12-14 | 2020-05-27 | ペメトレキセドまたはその薬剤学的に許容可能な塩を含有する安定化された薬学組成物 |
| JP2022088229A Pending JP2022107687A (ja) | 2015-12-14 | 2022-05-31 | ペメトレキセドまたはその薬剤学的に許容可能な塩を含有する安定化された薬学組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020091920A Pending JP2020125359A (ja) | 2015-12-14 | 2020-05-27 | ペメトレキセドまたはその薬剤学的に許容可能な塩を含有する安定化された薬学組成物 |
| JP2022088229A Pending JP2022107687A (ja) | 2015-12-14 | 2022-05-31 | ペメトレキセドまたはその薬剤学的に許容可能な塩を含有する安定化された薬学組成物 |
Country Status (9)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2019244965A1 (ja) * | 2018-06-20 | 2020-06-25 | 日本化薬株式会社 | ペメトレキセドナトリウム注射用溶液製剤、並びにその製造方法 |
| CN112138250B (zh) * | 2019-06-28 | 2023-04-14 | 四川普锐特药业有限公司 | 保持给药均一度的药物流体分配器及右美托咪定鼻喷器 |
| EP4537814A1 (en) * | 2022-06-09 | 2025-04-16 | Shanghai Aurora Biotechnology Co., Ltd. | Pemetrexed disodium liquid composition, preparation method therefor and use thereof |
| JP2024006619A (ja) | 2022-07-04 | 2024-01-17 | セイコーエプソン株式会社 | 印刷装置、情報処理装置、情報処理システム、処理方法、及び、プログラム |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0162654B1 (ko) | 1989-12-11 | 1998-11-16 | 알렌 제이. 시니스갤리 | N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체 |
| ATE267601T1 (de) * | 2000-02-04 | 2004-06-15 | Lilly Co Eli | Pharmazeutische zusammensetzung enthaltend pemetrexed zusammen mit monothioglycerol, l- cystein oder thioglykolsäure |
| US6686365B2 (en) | 2000-02-04 | 2004-02-03 | Eli Lilly And Company | Pharmaceutical composition |
| CA2804855A1 (en) * | 2010-07-28 | 2012-02-02 | Eagle Pharmaceuticals, Inc. | Pharmaceutical compositions containing pemetrexed having extended storage stability |
| KR20130122065A (ko) | 2012-04-30 | 2013-11-07 | 씨제이제일제당 (주) | 페메트렉시드를 함유하는 안정화된 주사용 액상 제제 |
| EP2666463A1 (en) * | 2012-05-21 | 2013-11-27 | Synthon BV | Stabilized liquid composition comprising pemetrexed |
| WO2013179248A1 (en) * | 2012-05-30 | 2013-12-05 | Fresenius Kabi Oncology Ltd. | Pharmaceutical compositions of pemetrexed |
| DE102012010774A1 (de) * | 2012-05-31 | 2013-12-05 | Stada Arzneimittel Ag | Pharmazeutische Pemetrexed-Lösung |
| KR101260636B1 (ko) | 2012-11-29 | 2013-05-13 | 씨제이제일제당 (주) | 안정화된 페메트렉시드 제제 |
| KR101485243B1 (ko) | 2013-05-08 | 2015-01-21 | 씨제이헬스케어 주식회사 | 안정화된 페메트렉시드 제제 |
| JP6094388B2 (ja) | 2013-06-07 | 2017-03-15 | ニプロ株式会社 | ペメトレキセドを含む注射用組成物 |
| EP3040074B1 (en) * | 2013-10-03 | 2018-07-25 | Fujifilm Corporation | Injection preparation and method for producing same |
| JP6099557B2 (ja) * | 2013-12-27 | 2017-03-22 | 富士フイルム株式会社 | 注射液製剤及びその製造方法 |
| KR101574875B1 (ko) | 2014-02-13 | 2015-12-04 | 건양대학교산학협력단 | 안정화된 페니실린 복합 현탁 제제 |
| DK3124026T3 (en) * | 2014-03-28 | 2018-10-01 | Fujifilm Corp | INJECTION PREPARATION AND METHOD OF PREPARING IT |
| US20170340639A1 (en) * | 2015-03-26 | 2017-11-30 | Ftf Pharma Private Limited | Pharmaceutical composition of pemetrexed |
| KR101919436B1 (ko) * | 2015-05-28 | 2018-11-16 | 주식회사 삼양바이오팜 | 안정화된 약학 조성물 및 그의 제조방법 |
-
2015
- 2015-12-14 KR KR1020150178339A patent/KR101693675B1/ko active Active
-
2016
- 2016-12-13 HK HK18114448.9A patent/HK1255313A1/zh unknown
- 2016-12-13 EP EP16876001.5A patent/EP3391908A4/en not_active Withdrawn
- 2016-12-13 MY MYPI2018702294A patent/MY191043A/en unknown
- 2016-12-13 CN CN201680073091.9A patent/CN108463251A/zh active Pending
- 2016-12-13 US US16/061,450 patent/US10792285B2/en not_active Expired - Fee Related
- 2016-12-13 JP JP2018550317A patent/JP2019502751A/ja active Pending
- 2016-12-13 WO PCT/KR2016/014594 patent/WO2017105059A1/ko not_active Ceased
-
2018
- 2018-06-14 PH PH12018501274A patent/PH12018501274A1/en unknown
-
2020
- 2020-05-27 JP JP2020091920A patent/JP2020125359A/ja active Pending
-
2022
- 2022-05-31 JP JP2022088229A patent/JP2022107687A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101260636B1 (ko) | 안정화된 페메트렉시드 제제 | |
| US9629844B2 (en) | Stabilized pemetrexed formulation | |
| JP2018109005A (ja) | ベンダムスチン製剤 | |
| SA518391187B1 (ar) | طرق لإنتاج صيغ علاجية ثابتة في مذيبات قطبية لا بروتونية | |
| US9662342B2 (en) | Formulations of cyclophosphamide liquid concentrate | |
| JP6094388B2 (ja) | ペメトレキセドを含む注射用組成物 | |
| DK2525796T3 (en) | An aqueous solution comprising 3-quinuclidinoner for the treatment of hyperproliferative disease, autoimmune disease and heart disease | |
| WO2013144814A1 (en) | Stable ready-to-use pharmaceutical composition of pemetrexed | |
| JP2020125359A (ja) | ペメトレキセドまたはその薬剤学的に許容可能な塩を含有する安定化された薬学組成物 | |
| JP2019502751A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| KR20200052326A (ko) | 코판리십의 제제 | |
| JPWO2008023807A1 (ja) | 安定化された医薬組成物 | |
| KR20130122065A (ko) | 페메트렉시드를 함유하는 안정화된 주사용 액상 제제 | |
| JP6873923B2 (ja) | 安定化された薬学組成物およびその製造方法 | |
| JP7400180B2 (ja) | 非経口製剤及びその使用 | |
| TW201716064A (zh) | 供治療癌症之口服投予紫杉醇及Ｐ－ｇｐ抑制劑的治療性組合 | |
| JP2025011312A (ja) | ｐ－ボロノフェニルアラニンを含有する注射液剤の析出防止方法 | |
| JP2006111614A (ja) | 安定化された注射用水溶液製剤 | |
| CN114423458A (zh) | 含有对二羟硼基苯丙氨酸的注射液剂 | |
| BR112023019005B1 (pt) | Preparação líquida de l-serina ou sal farmaceuticamente aceitável da mesma e método para preparar a mesma | |
| JP2016041684A (ja) | がん治療用医薬組成物 |